Accuray Inc (NASDAQ:ARAY) Reports Mixed Q4 2025 Earnings: Revenue Beat but EPS Miss Sparks 6% After-Hours Drop

Accuray Inc (NASDAQ:ARAY) reported its fourth-quarter and fiscal 2025 financial results, delivering mixed performance relative to analyst expectations. The company, which specializes in radiation therapy solutions, posted revenue of $127.5 million for Q4 2025, slightly above the consensus estimate of $126.2 million. However, earnings per share (EPS) came in at $0.00, missing the projected $0.0179.

Key Takeaways from the Earnings Report

• Revenue Beat, EPS Miss: While revenue exceeded expectations, the flat EPS disappointed investors, likely contributing to the stock's negative after-hours reaction, which saw a decline of over 6%.
• Service Growth Highlighted: The press release emphasized strong service revenue performance, suggesting that recurring revenue streams remain a stable part of Accuray’s business model.
• Debt Refinancing Completed: The company finalized a debt refinancing, which could improve its financial flexibility moving forward.
• Fiscal 2026 Guidance Issued: Accuray provided its outlook for the next fiscal year, though specific figures were not detailed in the initial release. Analysts currently project full-year 2026 revenue at $464.2 million, with an estimated EPS loss of $0.10965.

Market Reaction and Price Action

The immediate after-hours drop of 6% indicates investor dissatisfaction, likely tied to the EPS miss and uncertainty around future profitability. Over the past month, the stock had gained approximately 11%, suggesting some optimism ahead of earnings. However, the muted EPS performance appears to have tempered expectations.

Looking Ahead

For Q1 2026, analysts expect revenue of $99.8 million and an EPS loss of $0.0765. The company’s ability to meet or exceed these estimates will be critical in determining whether the post-earnings sell-off was an overreaction or a justified correction.

For a deeper dive into Accuray’s earnings history and future estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.